Stereotaxis (STXS) Q1 2026 earnings review
The Narrative Outpaces the Numbers
Stereotaxis characterizes this as an 'exciting period,' but Q1 financials highlight a painful transition. Total revenue reversed into a 16% YoY decline ($6.3M). The company is shedding its legacy Johnson & Johnson catheter dependency faster than it can scale its newly FDA-approved MAGiC catheters, causing high-margin recurring revenue to drop 10%. Management is banking on a massive back-half hockey stick—guiding for Q3 and Q4 revenues over $10M—but with only $14.6M in cash and a $3.5M quarterly free cash flow drain, execution risk is paramount.
🐂 Bull Case
The foundational product ecosystem is fully approved, with the MAGiC catheter and Synchrony digital operating room receiving FDA clearance in early 2026. This allows Stereotaxis to finally commercialize its end-to-end proprietary offering.
The definitive agreement to acquire Robocath provides a complementary robotic mechanism of action, expanding Stereotaxis's reach beyond electrophysiology into interventional cardiology and neurointerventions.
🐻 Bear Case
The wind-down of the legacy Johnson & Johnson relationship is severely pressuring the top line. Recurring revenue dropped 10% YoY to $5.0M, proving that the old revenue stream is decaying faster than the new one can currently replace it.
The company burned $3.5M in free cash flow this quarter and has only $14.6M in cash. If the projected Q3/Q4 revenue hockey stick is delayed by manufacturing bottlenecks, STXS will face an urgent liquidity squeeze.
⚖️ Verdict: 🔴
Bearish. Management's optimism is heavily reliant on future execution. A 16% revenue drop and tight cash reserves present immediate, tangible risks that overshadow the long-term potential of the newly approved product ecosystem.
Key Themes
The 'Exciting Period' Contradicted by Falling Sales
Despite management framing this as a historic inflection point, the data tells a story of decelerating momentum. System sales plunged 33% YoY (from $2.0M to $1.3M) and Disposables/Recurring revenue fell 10% YoY (from $5.5M to $5.0M). The narrative of a structurally transformed commercial opportunity has not yet translated to the P&L.
Manufacturing Ramp is Gating Growth
The transition to a proprietary catheter model is currently constrained by supply, not demand. Management explicitly noted that demand for MAGiC 'far exceeds supply.' The goal is to reach 500 catheters a month by year-end, but until then, this bottleneck is severely limiting the recurring revenue recovery.
Cash Burn vs Runway
Free cash flow worsened to -$3.5M in Q1 2026 compared to -$1.8M a year ago. With a total cash balance of just $14.6M and no debt, the margin for error is razor-thin. If the manufacturing scale-up falters, Stereotaxis may be forced into dilutive capital raises, contradicting management's belief that they can achieve profitability without 'substantial dilution.'
MAGiC and Synchrony Approvals Unlock the U.S.
The regulatory overhang is finally clear. The MAGiC cardiac ablation catheter received FDA approval in January, and the Synchrony digital operating room system was cleared in April. This transforms Stereotaxis from a capital equipment company dependent on third-party disposables into a fully integrated ecosystem.
Massive Unit Economics Improvement
While current volumes are low, the structural profitability of the new model is vastly superior. Management noted that disposable revenue per procedure for their proprietary catheters is 'several fold higher' than the legacy J&J model. Once supply constraints ease, this should trigger powerful gross margin expansion.
Robocath Acquisition Multiplies TAM
The definitive agreement to acquire Robocath is a major strategic pivot. By combining Stereotaxis's magnetic navigation with Robocath's mechanical robotic mechanism of action, the company can now address the full spectrum of endovascular procedures, effectively multiplying its Total Addressable Market (TAM) beyond electrophysiology.
Other KPIs
Accelerating. An impressive jump from 15% in Q1 2025. While total system revenue dropped, the mix shifted favorably, likely reflecting the premium pricing of the new GenesisX system installations compared to older, lower-margin equipment.
Stable. The company is successfully managing costs despite the massive product rollout and acquisition activity. Adjusted OpEx is slightly down from $6.8M a year ago, showing strict cost discipline while they wait for top-line revenue to materialize.
Guidance
Accelerating. This implies more than 23% growth over FY 2025's $32.4 million. Given the $6.3M result in Q1, the company is baking in an extreme growth ramp for the remaining three quarters.
Accelerating aggressively. To jump from $6.3M in Q1 to over $10M by Q3 requires flawless execution on the MAGiC catheter manufacturing ramp and strong, unhindered hospital adoption of the GenesisX system.
Key Questions
MAGiC Supply Chain Confidence
You noted that MAGiC demand far exceeds supply and you are targeting 500 units a month by year-end. What are the specific bottlenecks in the manufacturing process right now, and what gives you confidence this won't slip into 2027?
J&J Attrition Rate
Recurring revenue declined nearly 10% YoY. How rapidly is the legacy J&J business deteriorating compared to your internal models, and at what quarter do you expect proprietary catheter sales to finally outpace this legacy decay?
Liquidity and Cash Runway
With $14.6M in cash and a $3.5M quarterly FCF burn, the balance sheet is tight. You stated you can grow without 'substantial' dilution. Does this imply a small, strategic capital raise is on the table before the Q3/Q4 revenue ramp hits the cash flow statement?
Robocath Integration Timelines
With the Robocath acquisition bringing a new robotic mechanism of action, what is the timeline for integrating this technology into the Synchrony digital platform, and when should we expect revenue synergies?